SCHEMBL7183830

SCHEMBL7183830

Cc1ccc(C)c(C(=O)c2ccccc2[P](=O)C(=O)c2c(C)cccc2C)c1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.36
LMNA P02545 3/20 0.36
CYP2C9 P11712 3/20 0.36
MEN1 O00255 3/20 0.36
CYP3A4 P08684 2/20 0.36
CYP1A2 P05177 2/20 0.36
AKR1B10 O60218 1/20 0.36
TRPA1 O75762 1/20 0.36
ABCB11 O95342 1/20 0.36
DHFR P00374 1/20 0.36
MPO P05164 1/20 0.36
CHRM1 P11229 1/20 0.36
AKR1B1 P15121 1/20 0.36
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
HIF1A Q16665 1/20 0.36
NAPRT Q6XQN6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7174639 0.91 MEN1 (0.37) KMT2ALMNAMEN1ALDH1A1GAA
SCHEMBL7178036 0.90 KMT2A (0.37) KMT2ALMNACYP2C9MEN1CYP3A4
SCHEMBL7181446 0.90 GFER (0.36) KMT2ALMNACYP2C9MEN1CYP3A4
SCHEMBL7181167 0.89 LMNA (0.41) KMT2ALMNACYP2C9MEN1CYP3A4
SCHEMBL7177297 0.88 KMT2A (0.35) KMT2ALMNACYP2C9MEN1CYP3A4
SCHEMBL7188426 0.87 CA12 (0.38) KMT2ALMNAMEN1PTGS2HTT
SCHEMBL7180491 0.87 TAS2R14 (0.39) LMNACYP2C9CYP3A4TP53ALDH1A1
SCHEMBL7181633 0.87 ALDH1A1 (0.31) KMT2ALMNAMEN1HSD17B10ALDH1A1
SCHEMBL7180500 0.84 KMT2A (0.39) KMT2ALMNACYP2C9MEN1CYP3A4
SCHEMBL7174823 0.84 RORC (0.42) KMT2ALMNACYP2C9MEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885LMNA 3241/4885CYP2C9 1094/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885LMNA 3247/4885CYP2C9 1606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.